I
IMBiologics
Biotech & Life Sciences · Suwon-si, South Korea · Founded 2020
Research and Development of Antibody Therapeutics MoreLess
IMBiologics specializes in the research and development of innovative immunomodulatory antibody therapeutics aimed at treating autoimmune diseases and cancer. The company operates in the biopharmaceutical sector, focusing on creating novel drugs that help restore homeostasis, the body's natural balance. IMBiologics serves a global clientele, including healthcare providers and patients in need of advanced treatments for complex diseases. The business model revolves around leveraging proprietary platform technology and in-licensed drug candidates to accelerate drug development. Revenue is generated through licensing deals, partnerships, and the commercialization of its therapeutic products. The company has successfully raised significant funding, including a 4B KRW seed round and a 13B KRW Series A financing round, to support its R&D activities and growth initiatives.
Keywords: immunomodulatory, antibody therapeutics, autoimmune diseases, cancer, biopharmaceutical, homeostasis, platform technology, licensing deals, R&D, innovative drugs.
Company overview
IMBiologics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2020
- Headquarters
- Suwon-si, South Korea
- Employees
- —
- Open positions
- 1
- Dealroom signal
- 21.3
Valuation & funding
IMBiologics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Oct 2025 | $35M | $168M | Partners Investment · K2 Investment Partners · Korea Development Bank · QUAD Ventures | ↗ |
| SERIES BOther financing | Jul 2023 | $17M | $67M | Partners Investment · Atinum Investment · K2 Investment Partners · Wooshin Venture Investment | ↗ |
| SERIES AOther financing | Sep 2021 | $11M | $44M | Partners Investment · Timewise Investment · Atinum Investment · IMM Investment | ↗ |
| SEEDOther financing | Jan 2021 | $3.4M | $13M | Atinum Investment | ↗ |
Growth signals
IMBiologics website traffic
Latest recorded traffic for IMBiologics is 4.1K monthly website visits, down 59% over the last three months.
Comparisons
IMBiologics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
IMBiologics's talent
Source: Dealroom Talent Intelligence.
Investors
26 investors on IMBiologics's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where IMBiologics has talent and traffic
In the news
Latest news about IMBiologics
Recent press, funding announcements, and product moves mentioning IMBiologics — open to read from the original sources.
Market sentiment
What the market is saying about IMBiologics
An AI-synthesized read of the highest-engagement posts about IMBiologics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See IMBiologics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.